Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Total Current Liabilities: 2020-2024

Historic Total Current Liabilities for Mirum Pharmaceuticals (MIRM) over the last 5 years, with Dec 2024 value amounting to $126.6 million.

  • Mirum Pharmaceuticals' Total Current Liabilities rose 38.54% to $160.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $160.4 million, marking a year-over-year increase of 38.54%. This contributed to the annual value of $126.6 million for FY2024, which is 45.35% up from last year.
  • As of FY2024, Mirum Pharmaceuticals' Total Current Liabilities stood at $126.6 million, which was up 45.35% from $87.1 million recorded in FY2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Total Current Liabilities peaked at $126.6 million during FY2024, and registered a low of $18.5 million during FY2020.
  • In the last 3 years, Mirum Pharmaceuticals' Total Current Liabilities had a median value of $87.1 million in 2023 and averaged $92.8 million.
  • Data for Mirum Pharmaceuticals' Total Current Liabilities shows a peak YoY spiked of 130.72% (in 2021) over the last 5 years.
  • Over the past 5 years, Mirum Pharmaceuticals' Total Current Liabilities (Yearly) stood at $18.5 million in 2020, then spiked by 130.72% to $42.6 million in 2021, then soared by 51.96% to $64.7 million in 2022, then surged by 34.51% to $87.1 million in 2023, then soared by 45.35% to $126.6 million in 2024.